• Home
  •  > Grant Detail
  • By Concept
  • By Last Name
  • By Full Text

 

Grant Detail

The grant details show the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the Fingerprint of the grant. The source of grants for this application is NIH ExPORTER, so only NIH grants are included. More information is available at http://projectreporter.nih.gov/ExPORTER/default.aspx.



PROGRESSION OF HEART FAILURE

Hani N Sabbah

1 April 1994 - 31 December 2003
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Total Funding: $ 2,329,997

FY 2003
5R01HL049090-09
$ 309,936
FY 2002
5R01HL049090-08
$ 300,909
FY 2001
5R01HL049090-07
$ 253,318
FY 2000
2R01HL049090-06
$ 322,459
FY 1998
5R01HL049090-05
$ 247,359
FY 1997
5R01HL049090-04
$ 235,218
FY 1996
5R01HL049090-03
$ 228,688
FY 1995
5R01HL049090-02
$ 217,505
FY 1994
1R01HL049090-01A2
$ 214,605
 
 
$ 2,329,997
Abstract

Left ventricular (LV) dysfunction, once established, worsens over time, despite the absence of intercurrent adverse events. This LV deterioration often culminates in congestive heart failure (HF). The mechanisms responsible for this process are not fully understood. We and others have speculated that progression of LV dysfunction and subsequent transition to over HF may be due, in part, to progressive global LV remodeling, and the cellular level, to ongoing loss of cardiomyocytes and/or progressive worsening of intrinsic contractile dysfunction of residual myocytes. During the past funding cycle, we showed for the first time, that progressive LV dysfunction and dilation are accompanied by ongoing loss of viable myocardium. Pioneering studies by us in dogs with HF and by others, in end-stage, explanted failed human hearts, evoked cardiomyocyte apoptosis, as a potential cause of ongoing loss of viable myocardium in HF. While critical to our knowledge of the overall pathophysiology of HF, the true importance of these findings is tempered by the existence of a major gap in our understanding of the adaptations and/or maladaptations, inherent to the HF state, that drive the process of ongoing cardiac muscle cell death that ultimately leads to intractable HF. In this application, we propose new investigations intended to close this knowledge gap. Over the next 5 years, we propose to determine if a relationship exists between 1) the severity of LV dysfunction and the extent of cardiomyocyte apoptosis; 2) progression of LV dysfunction and the activity and expression of protein phosphatases; enzymes that have been suggested to promote apoptosis and have been shown by us to be elevated in HF; and 3) the severity of LV dysfunction and susceptibility of cardiomyocytes to undergo apoptosis mediated by norepinephrine, angiotensin-II and hypoxia; all of which are classic features of HF. We further propose to examine if in-vivo treatment of HF with vascular endothelial growth factor ameliorates the hypoxic state through angiogenesis and, in doing so, prevent hypoxia-mediated apoptosis and, consequently, prevent the progression to overt HF. Finally, we will address the role of a central adaptation in HF namely, whether the process of progressive LV dilation itself promotes cardiomyocyte loss or vice versa. We will test this by surgical placement of a passive constraining device around strengths of critical findings uncovered during the previous funding cycle and are in line with our overall objective of identifying the mechanisms of progressive deterioration of LV function that is characteristic of the HF state.

56 Resulting Publications

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.

Related Grants

Related Publications